The estimated Net Worth of Andrew A. Hindman is at least $9.28 Million dollars as of 18 November 2022. Mr. Hindman owns over 65,000 units of Theravance Biopharma Inc stock worth over $3,319,145 and over the last 10 years he sold TBPH stock worth over $2,199,235. In addition, he makes $3,757,960 as Chief Financial Officer and Senior Vice President at Theravance Biopharma Inc.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Mr. Hindman TBPH stock SEC Form 4 insiders trading
Andrew has made over 9 trades of the Theravance Biopharma Inc stock since 2015, according to the Form 4 filled with the SEC. Most recently he sold 65,000 units of TBPH stock worth $716,300 on 18 November 2022.
The largest trade he's ever made was selling 65,000 units of Theravance Biopharma Inc stock on 18 November 2022 worth over $716,300. On average, Andrew trades about 3,353 units every 72 days since 2014. As of 18 November 2022 he still owns at least 409,771 units of Theravance Biopharma Inc stock.
You can see the complete history of Mr. Hindman stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Andrew Hindman biography
Andrew Hindman serves as Chief Financial Officer, Senior Vice President of the Company. He has held several senior executive level positions in the biopharmaceutical industry, most recently as Chief Business Officer of Acorda Therapeutics since March 2018 and prior to that role he served as Chief Business Development Officer from May 2014 to March 2018. Before joining Acorda, from April 2011 to January 2014, Mr. Hindman served as President, Chief Executive Officer and member of the board of Tobira Therapeutics, a privately-held biotechnology company that was acquired by Allergan in 2016. Prior thereto, Mr. Hindman held senior corporate development and commercial operating positions, including from 2010 to 2011 at Nodality, Inc., from 2008 to 2010 at Onyx Pharmaceuticals, Inc., and from 1998 to 2008 at Gilead Sciences, Inc. Mr. Hindman holds a B.S. in MB&B (molecular biology and biochemistry) and economics from Wesleyan University, and an executive M.B.A. from Columbia University and the University of California, Berkeley, Haas School of Business.
What is the salary of Andrew Hindman?
As the Chief Financial Officer and Senior Vice President of Theravance Biopharma Inc, the total compensation of Andrew Hindman at Theravance Biopharma Inc is $3,757,960. There are 1 executives at Theravance Biopharma Inc getting paid more, with Rick Winningham having the highest compensation of $5,932,410.
How old is Andrew Hindman?
Andrew Hindman is 47, he's been the Chief Financial Officer and Senior Vice President of Theravance Biopharma Inc since 2019. There are 25 older and no younger executives at Theravance Biopharma Inc. The oldest executive at Theravance Biopharma Inc is Burton Malkiel, 87, who is the Independent Director.
What's Andrew Hindman's mailing address?
Andrew's mailing address filed with the SEC is C/O THERAVANCE BIOPHARMA US, INC., 901 GATEWAY BLVD, SOUTH SAN FRANCISCO, CA, 94080.
Insiders trading at Theravance Biopharma Inc
Over the last 10 years, insiders at Theravance Biopharma Inc have traded over $11,619,559 worth of Theravance Biopharma Inc stock and bought 4,008,513 units worth $29,986,832,769,275 . The most active insiders traders include Plc Gsk, Inc. Innoviva,, and Eli Samaha. On average, Theravance Biopharma Inc executives and independent directors trade stock every 57 days with the average trade being worth of $448,635. The most recent stock trade was executed by Eli Samaha on 7 August 2024, trading 999,800 units of TBPH stock currently worth $7,798,440.
What does Theravance Biopharma Inc do?
theravance biopharma is a biopharmaceutical company with one approved product, vibativ® (telavancin), that was discovered and developed internally, a pipeline of internally discovered product candidates and strategic collaborations with pharmaceutical companies.
What does Theravance Biopharma Inc's logo look like?
Complete history of Mr. Hindman stock trades at Acorda Therapeutics Inc and Theravance Biopharma Inc
Theravance Biopharma Inc executives and stock owners
Theravance Biopharma Inc executives and other stock owners filed with the SEC include:
-
Rick Winningham,
Chairman of the Board, Chief Executive Officer -
Andrew Hindman,
Chief Financial Officer, Senior Vice President -
Bradford Shafer,
Executive Vice President, General Counsel, Secretary -
Brett Haumann,
Senior Vice President, Clinical Development and Chief Medical Officer -
Frank Pasqualone,
Senior Vice President and Chief Commercial Operations Officer -
Philip Worboys,
Senior Vice President - Research and Translational Science -
Rick E. Winningham M.B.A.,
Chairman & CEO -
Andrew Asa Hindman,
Sr. VP & CFO -
Bradford J. Shafer,
Exec. VP, Gen. Counsel & Sec. -
Andrew Asa Hindman M.B.A,
Sr. VP & CFO -
Rhonda F. Farnum,
Chief Bus. Officer and Sr. VP of Commercial & Medical Affairs -
William Young,
Lead Independent Director -
Burton Malkiel,
Independent Director -
Donal O'Connor,
Independent Director -
Dean Mitchell,
Independent Director -
Susan Molineaux,
Independent Director -
Eran Broshy,
Independent Director -
Laurie Alsup,
Independent Director -
George Whitesides,
Independent Director -
Robert Gunderson,
Director -
Deepika Pakianathan,
Independent Director -
Vijay Sabesan,
Senior Vice President - Technical Operations -
Kenneth Pitzer,
Senior Vice President - Product Strategy and Commercial Planning -
Ann Brady,
President - Theravance Biopharma Ireland Limited -
Dr. Ann B. Brady Ph.D.,
Pres of Theravance Biopharma Ireland Limited -
Dr. Richard A. Graham Ph.D.,
Sr. VP of Devel. -
Daniel Long,
Head of Medicinal Chemistry -
Dr. Kenneth R. Pitzer,
Sr. VP of Product Strategy & Commercial Planning -
Dr. Phillip D. Worboys,
Sr. VP of Research & Translational Science -
Dennis O. Driver,
Sr. VP of HR, Organizational and Leadership Devel. -
Gail B. Cohen,
VP of Corp. Communications & Investor Relations -
Jeremy T Grant,
-
Renee D Gala,
VP-Finance -
Peter S Ringrose,
Director -
Junning Lee,
Sr. VP, Technical Operations -
Sharathchandra S Hegde,
SVP, Research -
Henrietta Fore,
Director -
Shehnaaz Suliman,
SVP, Corp Dev & Strategy -
Jeffrey David Jonker,
Senior VP, Corp. & Bus. Dev. -
Michael G Atieh,
Director -
Leonard M Blum,
Sr VP, Chief Comm. Officer -
Inc. Innoviva,,
10% owner -
Mathai Mammen,
SVP, Research & Early Clin Dev -
Rhonda Farnum,
SVP, COMM & MEDICAL AFFAIRS -
Richard A Graham,
SVP, RESEARCH & DEVELOPMENT -
Plc Gsk,
-
Aziz Sawaf,
SVP & CHIEF FINANCIAL OFFICER -
Brett A. Grimaud,
SVP, GEN COUNSEL AND SECRETARY -
Susannah Gray,
-
Aine Miller,
SVP, DEV & HEAD OF IRE OFFICE -
Eli Samaha,
10% owner